contractpharmaMarch 16, 2020
Tag: Biogen , COVID-19 , Vir Biotechnology , antibody
Biogen and Vir Biotechnology have entered an antibody development and manufacturing agreement to develop Vir's monoclonal antibodies against coronavirus.
Under the agreement, Biogen will provide cell line development, process development and clinical manufacturing for Vir's monoclonal antibodies. Vir has discovered antibodies that bind to the novel coronavirus, and is testing whether they can treat or prevent the infection.
"Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies," said George Scangos, Vir's CEO.
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: